This website isn’t supported by Internet Explorer. We recommend that you use a different browser (e.g. Edge, Chrome, Firefox, Safari, or similar) for the best experience of our content.
More

The following featured medical education activities are developed and offered independently by third-party providers through an unrestricted grant from Novo Nordisk. They are independent, evidenced-based, and fair-balanced educational activities that enhance the knowledge, skills, and performance of healthcare professionals (HCP), patients, and communities. These activities are non-promotional in nature and can be accredited or non-accredited; and the programme and content are always decided independently from industry supporters.

SCOPE is one of the internationally-recognised certification in obesity management. It equips health professionals with up to date, evidence-based obesity management resources, to better Treat People and adolescents with obesity and to excel in their careers. SCOPE offers 40+ free e-learning modules on specific issues around obesity, a Core Learning Path containing the essential information on obesity management and SCOPE School one day courses.

 

Made for:

Primary Care Physicians, Specialists, dietitians, clinical pharmacist

 

Disease areas:

Obesity

 

Developed by:

World Obesity Federation

Click here to register →

ASCEND is an award-winning, digital streaming platform designed to improve the care of people with obesity and diabetes. Accredited, multi-format, multi-language content provides primary care physicians with practical, interactive micro-learning about weight and diabetes management. Endorsed by EASO, WONCA Europe and PCDE, visit ASCEND to hear world-leading experts share their clinical insights, talk through case studies, address frequently asked questions, and much more!

 

Led by an international faculty, ASCEND provides independent interactive e-learning that will enable health care professionals to provide patient-centred care. It offers more than 25 hours of digital content supported by AI recommendations on diabetes and obesity management.

 

Made for:

Primary Care Physicians

 

Disease areas:

Diabetes, Obesity

 

Developed by:

International Medical Press

 

Click here to register

Recent developments in insulin therapy focusing on new formulations or routes of administration and the evolving usage of continuous glucose monitoring (CGM) have opened new frontiers in the management of both type 1 and type 2 diabetes mellitus (T1DM and T2DM). While novel faster- or longer-acting insulins are expanding the options in diabetes management, the ever-growing integration of CGM in clinical practice is also contributing to the transformation of diabetes care over the last decade. In this program, key opinion leaders in diabetes from across the globe will take the audience on a journey to these new frontiers in diabetes care.

 

Made for:

Diabetologists/Endocrinologists, Primary Care Physicians

 

Disease areas:

Diabetes

 

Developed by:

Medscape Education Global

 

Click here to register →

Data from recent clinical and cardiovascular outcomes trials (CVOTs) suggest that glucagon-like peptide-1 (GLP-1) receptor agonists have multi-factorial benefits beyond glycaemic control. 

 

On this programme, you'll find a collection of dynamic, interactive educational courses addressing the latest evidence for managing individuals with diabetes and other disorders—especially established or risk factors for atherosclerotic cardiovascular disease (ASCVD) and chronic kidney disease (CKD).

 

Made for:

Specialists, Primary Care Physicians

 

Disease areas:

Diabetes, Cardiovascular Disease, Chronic Kidney Disease

 

Developed by:

Medscape Education Global

 

See for yourself →

2020’s shift to virtual editions of the major scientific congresses marked a new era for communicating the results of ground breaking research in topics that affect clinical practice. This page is dedicated to updates in promising new pharmacologic agents for management of diabetes and metabolic disorders, and related conditions including non-alcoholic steatohepatitis (NASH) and cardiovascular disease (CVD), from GLP-1 receptor agonists through novel insulins, to primary and secondary prevention of micro- and macrovascular complications of diabetes, and obesity management. Join us for a virtual journey to these new frontiers in patient care as you listen to experts in diabetes, metabolic disorders, and CVD from across the globe discuss new data and recent publications in mature, growing, and emerging fields of diabetes care.


Made for:

Gastroenterologists, Diabetologists, Endocrinologists, Primary Care Physicians

 

Disease areas:

Diabetes, Non-Alcoholic Steatohepatitis, Cardiovascular Disease, Chronic Kidney Disease

 

Developed by:

Medscape Education Global

 

See for yourself →

The prevalence of non-alcoholic fatty liver disease (NAFLD) and its progression to the more serious non-alcoholic steatohepatitis (NASH) are increasing globally. The rising NAFLD/NASH prevalence is closely linked to the rising global obesity and type 2 diabetes epidemics. There are currently no approved therapeutics for the management of NAFLD/NASH. Disease is generally managed with lifestyle modification including diet and exercise. As a result it is critical to identify NAFLD early in patients to minimize progression to NASH, cirrhosis, and eventually hepatocellular carcinoma. This curriculum will highlight NASH as a metabolic disorder and will emphasize the need for early detection, risk assessment, and treatment to prevent progression of this rising epidemic.

 

Made for:

Gastroenterologists, Diabetologists, Endocrinologists

 

Disease areas:

Non-Alcoholic Steatohepatitis

 

Developed by:

Medscape Education Global

 

See for yourself →

Worldwide, patients with diabetes or obesity face additional risks and concerns in the COVID-19 pandemic. Healthcare professionals are having to change their practice in response to the new and changing landscape of care and help their patients meet and manage the potential threats and social realities of living during this outbreak of a novel coronavirus. This dynamic collection of free educational activities brings together cross-disciplinary teams of experts from around the world to assess these challenges and offer practical guidance.

 

Made for:

Healthcare Professionals treating diabetes and obesity

 

Disease areas:

Diabetes, Obesity

 

Developed by:

Medscape Education Global

 

See for yourself →

The hub includes a practical guide to treatment, a drug category overview and interactive patient case studies for GPs, as well as a roundtable discussion between two diabetes specialists. Lastly, an article, written based on the opinions and advice provided by a select panel of experts, is hosted on the hub where the challenges in the clinical management of type 2 diabetes are discussed.

 

On the ‘Practical guide to treatment’ page, the reader can walk through an interactive algorithm that is based on the most recent national and international guidelines on the management of type 2 diabetes and the associated comorbidities. This allows the GP to think about a holistic approach to patient management.

 

On the ‘Drug category overview’ page, the reader can view key points on the efficacy and safety profiles of type 2 diabetes drugs.

 

The 'interactive patient case studies' follow two patients over a period of 6-10 years where the user is asked to make decisions on managing their condition.

 

The 'roundtable discussion' is a conversation between Dr Patrick Holmes, a GPwSI in diabetes based in the UK and Dr Marcel Kaiser, an internist and diabetologist from Germany. In the video, the Dr Holmes and Dr Kaiser cover points such as why the role of the primary care physician in the management of type 2 diabetes is more important than ever before.

 

Made for:

Primary Care Physicians

 

Disease areas:

Diabetes

 

Developed by:

M3

 

linkText →